Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
13 January 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
26 September 2024
Legal News: International Trade Enforcement & Compliance
Five Compliance Best Practices for … Drafting Legal Terms and Conditions
Drafting clear and effective legal terms and conditions is crucial for establishing a legally binding agreements between parties while minimizing the risk of disputes or misunderstandings.
26 September 2024
Legal News: International Trade Enforcement & Compliance
What Every Multinational Company Should Know About … Implementing Compliance Audits
Most multinational companies are aware of the need for robust compliance programs consisting of risk assessments, policies, and procedures adopted to mitigate identified compliance risks, and identifying and responding to violations of policies and procedures (or laws and regulations).
26 September 2024
Viewpoints
DOJ Stresses AI Risk and Whistleblower Protection in Revised Corporate Compliance Guidance
On Monday, September 23, DOJ’s Criminal Division announced updates to its guidance for evaluating corporate compliance programs.